biomolecules Review Circulating Extracellular Vesicles As Biomarkers and Drug Delivery Vehicles in Cardiovascular Diseases Renata Caroline Costa de Freitas 1,2 , Rosario Dominguez Crespo Hirata 2 , Mario Hiroyuki Hirata 2 and Elena Aikawa 1,3,4,* 1 Center for Interdisciplinary Cardiovascular Sciences, Division of Cardiovascular Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115, USA;
[email protected] 2 Department of Clinical and Toxicological Analyses, School of Pharmaceutical Sciences, University of Sao Paulo, Sao Paulo 05508-000, Brazil;
[email protected] (R.D.C.H.);
[email protected] (M.H.H.) 3 Center for Excellence in Vascular Biology, Division of Cardiovascular Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115, USA 4 Department of Human Pathology, Sechenov First Moscow State Medical University, 119992 Moscow, Russia * Correspondence:
[email protected]; Tel.: +1-617-730-7755 Abstract: Extracellular vesicles (EVs) are composed of a lipid bilayer containing transmembrane and soluble proteins. Subtypes of EVs include ectosomes (microparticles/microvesicles), exosomes, and apoptotic bodies that can be released by various tissues into biological fluids. EV cargo can modulate physiological and pathological processes in recipient cells through near- and long-distance intercellular communication. Recent studies have shown that origin, amount, and internal cargos (nucleic acids, proteins, and lipids) of EVs are variable under different pathological conditions, including cardiovascular diseases (CVD). The early detection and management of CVD reduce premature morbidity and mortality. Circulating EVs have attracted great interest as a potential biomarker for diagnostics and follow-up of CVD. This review highlights the role of circulating EVs Citation: de Freitas, R.C.C.; Hirata, as biomarkers for diagnosis, prognosis, and therapeutic follow-up of CVD, and also for drug delivery.